Malaria during pregnancy and transplacental transfer of Kaposi sarcoma-associated herpesvirus (KSHV) antibodies: a cohort study of Kenyan mother and child pairs
Background: Kaposi sarcoma-associated herpesvirus (KSHV) seroprevalence in sub-Saharan African kids can vary as much as 50% by age 2 years however components affecting early age of KSHV an infection should not effectively understood. Malaria throughout being pregnant has been related to hindered transplacental switch of antibodies to a number of pathogens however whether or not it impacts transplacental switch of KSHV antibodies is unknown. We aimed to find out if in utero malaria publicity decreased the switch of KSHV antibodies throughout the placenta.
Strategies: A cohort examine in Kisumu, Kenya enrolled pregnant ladies at their first antenatal clinic (ANC) go to and adopted them via supply. We included 70 KSHV-positive, HIV-negative moms and their kids. KSHV antibody ranges have been measured by ELISA (K8.1, ORF73) and multiplex assay. Transplacental switch of antibodies was measured by the wire to maternal blood ratio (CMR) of KSHV antibodies. Malaria throughout being pregnant was outlined as detection of Plasmodium falciparum (Pf) DNA at any ANC go to or supply. Amongst ladies with malaria throughout being pregnant, we examined time of final malaria an infection previous to supply and malaria incidence fee.
Outcomes: KSHV seroprevalence (constructive for K8.1 or ORF73 by ELISA) amongst pregnant ladies was 88%. Neither malaria throughout being pregnant, malaria an infection timing, nor MIR have been related to maternal supply KSHV antibody blood ranges. Maternal supply and twine blood KSHV antibody ranges have been extremely correlated however these correlations didn’t differ by malaria throughout being pregnant. KSHV transplacental antibody switch was not related to malaria throughout being pregnant, malaria an infection timing, nor MIR.
Conclusions: Malaria throughout being pregnant doesn’t seem to have an effect on switch of KSHV antibodies throughout the placenta.
Dynamic modifications in anti-SARS-CoV-2 antibodies throughout SARS-CoV-2 an infection and restoration from COVID-19
Deciphering the dynamic modifications in antibodies in opposition to SARS-CoV-2 is important for understanding the immune response in COVID-19 sufferers. Right here we analyze the laboratory findings of 1,850 sufferers to explain the dynamic modifications of the whole antibody, spike protein (S)-, receptor-binding area (RBD)-, and nucleoprotein (N)-specific immunoglobulin M (IgM) and G (IgG) ranges throughout SARS-CoV-2 an infection and restoration. The era of S-, RBD-, and N-specific IgG happens one week later in sufferers with extreme/essential COVID-19 in comparison with sufferers with gentle/average illness, whereas S- and RBD-specific IgG ranges are 1.5-fold greater in extreme/essential sufferers throughout hospitalization. The RBD-specific IgG ranges are 4-fold greater in older sufferers than in youthful sufferers throughout hospitalization.
As well as, the S- and RBD-specific IgG ranges are 2-fold greater within the recovered sufferers who’re SARS-CoV-2 RNA damaging than those that are RNA constructive. Decrease S-, RBD-, and N-specific IgG ranges are related to a decrease lymphocyte proportion, greater neutrophil proportion, and an extended period of viral shedding. Sufferers with low antibody ranges on discharge would possibly thereby have a excessive probability of being examined constructive for SARS-CoV-2 RNA after restoration. Our examine gives necessary data for COVID-19 analysis, remedy, and vaccine growth.
Throughout the coronavirus illness 2019 (COVID-19) pandemic, many international locations skilled an infection in healthcare staff (HCW) resulting from overburdened healthcare techniques. Nevertheless, whether or not contaminated HCW purchase protecting immunity in opposition to SARS-CoV-2 is unclear. Right here, we characterised SARS-CoV-2-specific antibody responses in Norwegian HCW in a potential cohort examine.
Malaria during pregnancy and transplacental transfer of Kaposi sarcoma-associated herpesvirus (KSHV) antibodies: a cohort study of Kenyan mother and child pairs
A randomized, multicentre, open-label section II proof-of-concept trial investigating the medical efficacy and security of the addition of convalescent plasma to the usual of care in sufferers hospitalized with COVID-19: the Donated Antibodies Working in opposition to nCoV (DAWn-Plasma) trial
Background: The COVID-19 pandemic has imposed an infinite burden on well being care techniques all over the world. Up to now, the administration of convalescent plasma of sufferers having recovered from SARS and extreme influenza to sufferers actively having the illness confirmed promising results on mortality and appeared secure. Whether or not or not this additionally holds true for the novel SARS-CoV-2 virus is at present unknown.
Strategies: DAWn-Plasma is a multicentre nation-wide, randomized, open-label, section II proof-of-concept medical trial, evaluating the medical efficacy and security of the addition of convalescent plasma to the usual of care in sufferers hospitalized with COVID-19 in Belgium. Sufferers hospitalized with a confirmed analysis of COVID-19 are eligible when they’re symptomatic (i.e. medical or radiological indicators) and have been recognized with COVID-19 within the 72 h earlier than examine inclusion via a PCR (nasal/nasopharyngeal swab or bronchoalveolar lavage) or a chest-CT scan displaying options suitable with COVID-19 within the absence of an alternate analysis. Sufferers are randomized in a 2:1 ratio to both customary of care and convalescent plasma (energetic remedy group) or customary of care solely. The energetic remedy group receives 2 items of 200 to 250 mL of convalescent plasma inside 12 h after randomization, with a second administration of two items 24 to 36 h after ending the primary administration. The trial goals to incorporate 483 sufferers and can recruit from 25 centres throughout Belgium. The first endpoint is the proportion of sufferers that require mechanical air flow or have died at day 15. The primary secondary endpoints are medical standing on day 15 and day 30 after randomization, as outlined by the WHO Development 10-point ordinal scale, and security of the administration of convalescent plasma.
Description: MIP-3 is a CC chemokine that signals through the CCR1 receptor. MIP-3 chemoattracts monocytes, resting T-lymphocytes and neutrophils, but does not chemoattract activated lymphocytes. Additionally, MIP-3 has been shown to inhibit colony formation of bone marrow myeloid immature progenitors. Recombinant human MIP-3 is an 11.3 kDa protein containing 99 amino acid residues, including the four highly conserved cysteine residues present in CC chemokines.
Description: Recombinant MIP-3(CCL-23) is a disulfide-linked monomeric protein consisting of 100 amino acid residues and migrates as an approximately 11 kDa protein under non-reducing conditions and reducing conditions in SDS-PAGE. Optimized DNA sequence encoding Human MIP-3 mature chain was expressed in E. coli.
Description: Recombinant MIP-3 alpha (CCL20) is a disulfide-linked monomeric protein consisting of 71 amino acid residues and migrates as an approximately 8 kDa protein under non-reducing conditions and reducing conditions in SDS-PAGE. Optimized DNA sequence encoding Human MIP-3 alpha mature chain was expressed in E. coli.
Description: Recombinant MIP-3(CCL-23) is a disulfide-linked monomeric protein consisting of 100 amino acid residues and migrates as an approximately 11 kDa protein under non-reducing conditions and reducing conditions in SDS-PAGE. Optimized DNA sequence encoding Human MIP-3 mature chain was expressed in E. coli.
Description: Recombinant MIP-3(CCL-23) is a disulfide-linked monomeric protein consisting of 100 amino acid residues and migrates as an approximately 11 kDa protein under non-reducing conditions and reducing conditions in SDS-PAGE. Optimized DNA sequence encoding Human MIP-3 mature chain was expressed in E. coli.
Description: MIP-3β is a CC chemokine that is expressed in the thymus, lymph nodes and in activated bone marrow stromal cells and signals through the CCR7 receptor. MIP-3β is a chemoattractant for T and B lymphocytes and myeloid progenitor cells. Human MIP-3β is active on murine cells. Recombinant human MIP-3β is an 8.8 kDa protein containing 77 amino acid residues, including the four highly conserved cysteine residues present in CC chemokines.
Description: MIP-3α is a CC chemokine that is expressed in the liver, lymph nodes, appendix, PBL and lung and can signal through the CCR6 receptor. MIP-3α is chemotactic towards lymphocytes and dendritic cells. Additionally, it promotes the adhesion of memory CD4+ T cells and inhibits colony formation of bone marrow myeloid immature progenitors. Recombinant human MIP-3α is an 8.0 kDa protein containing 70 amino acid residues, including the four highly conserved cysteine residues present in CC chemokines.
Description: Enzyme-linked immunosorbent assay kit for quantification of Human MIP-3 Alpha/CCL20 in samples from serum, plasma, tissue homogenates and other biological fluids.
Description: Enzyme-linked immunosorbent assay kit for quantification of Human CCL19/MIP-3 Beta in samples from serum, plasma, tissue homogenates and other biological fluids.
Description: Chemokine (C-C motif) ligand 19 (CCL19) is a protein that in humans is encoded by the CCL19 gene. This gene is one of several CC cytokine genes clustered on the p-arm of chromosome 9. Cytokines are a family of secreted proteins involved in immunoregulatory and inflammatory processes. The CC cytokines are proteins characterized by two adjacent cysteines. The cytokine encoded by this gene may play a role in normal lymphocyte recirculation and homing. It also plays an important role in trafficking of T cells in thymus, and in T cell and B cell migration to secondary lymphoid organs. It specifically binds to chemokine receptor CCR7.
Description: Macrophage Inflammatory Protein 3 alpha (MIP-3 alpha), is also called Chemokine, cc motif, ligand 20 (CCL20). The MIP-3 alpha / CCL20 gene was cloned and sequenced, revealing a four exon, three intron structure, and was localized by FISH analysis to 2q35-q36. MIP3 alpha is predominantly expressed in lymph nodes, appendix, PBL, fetal liver, fetal lung and several cell lines. MIP3 alpha / CCL20 and its receptor CCR6 are markedly up-regulated in psoriasis, and they may play a role in the recruitment of T cells to lesional psoriatic skin.
Description: A polyclonal antibody against MIP. Recognizes MIP from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, IHC;ELISA:1:500-1:5000, IHC:1:50-1:200
Description: A polyclonal antibody against MIP. Recognizes MIP from Human. This antibody is Unconjugated. Tested in the following application: ELISA, IHC;ELISA:1:1000-1:5000, IHC:1:50-1:200
Description: A polyclonal antibody against MIP. Recognizes MIP from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, IHC;ELISA:1:1000-1:5000, IHC:1:50-1:200
Description: A polyclonal antibody against MIP. Recognizes MIP from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, IHC;ELISA:1:2000-1:5000, IHC:1:20-1:100
Description: A polyclonal antibody against MIP. Recognizes MIP from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB
Description: A polyclonal antibody against MIP. Recognizes MIP from Human. This antibody is Unconjugated. Tested in the following application: ELISA, IHC, IF; Recommended dilution: IHC:1:200-1:500, IF:1:50-1:200
Description: A polyclonal antibody against mip. Recognizes mip from Legionella pneumophila. This antibody is Unconjugated. Tested in the following application: ELISA
Description: A polyclonal antibody against MIP. Recognizes MIP from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: WB, IHC, ELISA;WB:1/500-1/2000.IHC:1/100-1/300.ELISA:1/5000
Description: MIP-3 is a CC chemokine that signals through the CCR1 receptor. MIP-3 chemoattracts monocytes, resting T-lymphocytes and neutrophils, but does not chemoattract activated lymphocytes. Additionally, MIP-3 has been shown to inhibit colony formation of bone marrow myeloid immature progenitors. Recombinant human MIP-3 is an 11.3 kDa protein containing 99 amino acid residues, including the four highly conserved cysteine residues present in CC chemokines.
Description: MIP-3 is a CC chemokine that signals through the CCR1 receptor. MIP-3 chemoattracts monocytes, resting T-lymphocytes and neutrophils, but does not chemoattract activated lymphocytes. Additionally, MIP-3 has been shown to inhibit colony formation of bone marrow myeloid immature progenitors. Recombinant human MIP-3 is an 11.3 kDa protein containing 99 amino acid residues, including the four highly conserved cysteine residues present in CC chemokines.
Description: MIP-4 is a CC chemokine that is expressed in lymph nodes, lungs, placenta and bone marrow. MIP-4's primary receptor is unknown. MIP-4 chemoattracts lymphocytes, and has been shown to exert activity on both CD4+ and CD8+ T cells. Recombinant human MIP-4 is a 7.8 kDa protein containing 68 amino acid residues, including the four highly conserved cysteine residues present in CC chemokines.
Description: MIP-5 is a CC chemokine that is expressed in the heart, skeletal muscle and adrenal gland. MIP-5 primarily signals through he CCR1 receptor, but also has been found to bind to CCR3. MIP-5 is chemotactic towards T cells and monocytes. Recombinant human MIP-5 is a 10.1 kDa protein containing 92 amino acid residues, including the four highly conserved cysteine residues present in CC chemokines.
Description: Description of target: Macrophage inflammatory protein-1 alpha (MIP-1 alpha), also called CCL3, LD78. The cDNA for MIP-1 alpha predicts a mature peptide of 69 amino acids with a molecular mass of 7,889 daltons.1 LD78 is a member of a newly identified superfamily of small inducible proteins involved in inflammatory responses, wound healing and tumorigenesis. MIP-1 alpha is a chemokine that has pro-inflammatory and stem cell inhibitory activities in vitro. It constitutes an important second signal for mast cell degranulation in the conjunctiva in vivo and consequently for acute-phase disease. The standard product used in this kit is recombinant human MIP-1α, consisting of 66 amino acids with the molecular mass of 7.5kDa.;Species reactivity: Human;Application: ELISA;Assay info: ;Sensitivity: < 10 pg/mL
Description: Description of target: Macrophage Inflammatory Protein 3α (MIP3α), also called Chemokine, cc motif, ligand 20 (CCL20). The MIP-3alpha/CCL20 gene was cloned and sequenced, revealing a four exon, three intron structure, and was localized by FISH analysis to 2q35-q36. MIP3α is predominantly expressed in lymph nodes, appendix, PBL, fetal liver, fetal lung and several cell lines. MIP3α/CCL20 and its receptor CCR6 are markedly up-regulated in psoriasis, and they may play a role in the recruitment of T cells to lesional psoriatic skin. And Alanine MIP-3α and Serine MIP-3α, the two forms of MIP3α, that differ by one amino acid at the predicted signal peptide cleavage site. Both of them were chemically synthesized and tested for biological activity. And both flu antigen plus IL-2-activated CD4(+) and CD8(+) T lymphoblasts and cord blood-derived dendritic cells responded to Ser and Ala MIP-3α.;Species reactivity: Human;Application: ELISA;Assay info: ;Sensitivity: < 1 pg/mL
Description: A polyclonal antibody raised in Goat that recognizes and binds to Human Goat Anti-CXCL2 / MIP-2 . This antibody is tested and proven to work in the following applications:
Description: A sandwich CLIA kit for quantitative measurement of Human MIP-3? (Macrophage Inflammatory Protein 3 Alpha) in samples from Serum, Plasma, Cell supernatant
×
Dialogue: This trial will both present assist or discourage the usage of convalescent plasma as an early intervention for the remedy of hospitalized sufferers with COVID-19 an infection.
